SONN Profile
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotechnology company specializing in the development of innovative biologic therapies with a focus on oncology. The company leverages its proprietary platform to create biologic medicines with single or bispecific actions. Central to its technology is the fully human albumin binding platform, which employs human single-chain antibody fragments that bind to human serum albumin, facilitating targeted delivery of therapeutics to specific tissues. This approach enhances the efficacy and precision of treatment by ensuring that the therapeutic agents are transported directly to the desired locations within the body.
Sonnet BioTherapeutics' lead product candidate, SON-1010, is a fully human version of interleukin 12, which is being investigated for its potential to treat non-small cell lung cancer and head and neck cancer. Currently undergoing Phase 1 clinical trials, SON-1010 represents a significant advancement in the treatment of these challenging cancer types. In addition, the company is developing SON-080, a fully human version of interleukin 6 aimed at addressing chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. SON-080 is currently in Phase Ib/IIa clinical studies. Another key product in the company's pipeline is SON-1210, a bispecific compound designed for solid tumor indications such as colorectal cancer.
Sonnet BioTherapeutics has also established a strategic licensing agreement with New Life Therapeutics Pte, Ltd. under which it will develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. This collaboration underscores the company's commitment to advancing its biologic therapies and expanding its reach in the oncology and broader therapeutic markets. The company's focus on leveraging its proprietary technology platforms aims to address unmet medical needs and provide new treatment options for patients suffering from various forms of cancer and other serious conditions.
Founded and headquartered in Princeton, New Jersey, Sonnet BioTherapeutics Holdings, Inc. continues to advance its clinical programs and explore new opportunities for its innovative biologic therapies. The company’s dedication to developing cutting-edge treatments positions it as a key player in the biotechnology sector, with a strategic emphasis on bringing novel solutions to market for complex and underserved medical conditions.
|
